Day: June 17, 2024

Adds Product Development & QC Labs, Fully-Automated IVD Vial-Filling Capability MISSISSAUGA, Ontario, June 17, 2024 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces its hosting of Associate Minister of Small Business of Ontario, the Honourable Nina Tangri, to celebrate the opening of two expansions to its medical devices manufacturing capacity at one of its three adjacent Mississauga sites. Expansion one is a new 2,000 square foot laboratory (“Lab”) to fulfill growing demand for Microbix’s quality assessment products (“QAPs™”) for diagnostic test-makers and other end-users, as well as for the internal quality control (“QC”) testing required to validate and release commercial production batches. The Lab may also be used for...

– Significant YoY improvement in operating performance – – Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities – MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, announced that it has received notice from the Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) in connection with the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 with the Securities and Exchange Commission. Summary First Quarter 2024 Results For the quarter ended March 31, 2024, the Company had a loss from operations of $4.1 million, a 29% improvement from the $5.8 million loss from...

ANN ARBOR, Mich., June 17, 2024 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has successfully completed cocoon production for the first commercial production run of its BAM-1 hybrids. The Company launched the BAM-1 hybrids 30 days ahead of schedule based on the overwhelming success of its spring production trials. During the spring trials, Kraig labs raised the two separate BAM-1 parental lines with overwhelming success. At the end of those trials, the BAM-1 parent lines were cross-mated to create this first batch of commercial production BAM-1 hybrids. This rearing of the BAM-1 hybrids represents a 10X increase in production volume when compared to the spring trials. This cycle has generated more than 325 pounds of recombinant...

Naples, FL, June 17, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a premier company in the acquisition and management of music royalties, is delighted to announce the acquisition of royalty-generating intellectual property in “FAMILY ONLY” by DaniLeigh. This acquisition underscores the company’s strategic efforts to enhance its portfolio with valuable assets from prominent artists. “FAMILY ONLY” by DaniLeigh is a track that has captivated listeners and continues to perform well across various platforms. This acquisition aims to leverage its revenue potential for long-term growth. Watch “FAMILY ONLY” by DaniLeigh here.About Music Licensing, Inc. (OTC: SONG) (ProMusicRights.com) Music Licensing, Inc. (OTC: SONG), also known as Pro Music Rights, is a diversified holding company...

Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigue Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scores Keros will host a corporate update call and webcast today, June 17, 2024, at 8:00 a.m. ETLEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing...

PORTLAND, Tenn., June 17, 2024 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (Nasdaq: SHLS), a global leader in electrical balance of system (EBOS) solutions for the energy transition market, today announced its launch of a comprehensive range of system-solutions focused on international developers and engineering, procurement and construction (EPC) contractors. The new product launch will take place at Intersolar Europe, June 19-21 and will introduce the most comprehensive suite of solutions by Shoals to-date, specifically designed with global customers in mind. The rollout will include solutions that enable unobstructed rows, agri-solar, as well as North-South configurations in addition to existing East-West configuration solutions. “Our new suite of solutions is bringing exciting innovations in the utility scale solar industry,”...

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. “We are excited to reach this R&D milestone with ZW171, reflecting our commitment to advancing innovative therapies for cancer treatment,” said Paul Moore, Chief Scientific Officer of Zymeworks. “ZW171’s unique design is intended to address the limitations of current bispecific T-cell engagers by enhancing tumor selectivity and...

French limited company (Société anonyme)with registered capital of 106,945,095 eurosRegistered office: 14, rue Royale, 75008 Paris632 012 100 R.C.S. ParisLegal Entity Identifier: 529900JI1GG6F7RKVI53 Pursuant to article L-233-8 II of the French “Code de Commerce” and223-16 of the AMF’s General Regulations:Total number of shares 534,725,475Number of real voting rights (excluding treasury shares) 534,725,475Theoretical number of voting rights (including treasury shares*)(*) pursuant to article 223-11 of the AMF’s General Regulations 534,725,475About L’Oréal For 115 years, L’Oréal, the world’s leading beauty player, has devoted itself to one thing only: fulfilling the beauty aspirations of consumers around the world. Our purpose, to create the beauty that moves the world, defines our approach to beauty as essential,...